Publication
Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma.
Estefania Gauto Mariotti, Shaji Kumar, Wilson Gonsalves, Prashant Kapoor, Francis Buadi, Suzanne Hayman, Nadine Abdallah, Moritz Binder, Joselle Cook, Angela Dispenzieri, David Dingli, Morie A Gertz, Taxiarchis Kourelis, Nelson Leung, Yi Lin, Mustaqeem Siddiqui, Ronald Go, Eli Muchtar, Rahma Warsame, Dragan Jevremovic, Robert A Kyle, S Vincent Rajkumar, Saurabh Zanwar
- Source
- PubMed
- Retrieved
- Oct 1, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261001-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Measurable residual disease (MRD) assessment has become central to risk-adapted treatment strategies in multiple myeloma, yet the prognostic value of MRD negativity following autologous stem cell transplantation (ASCT) across individual high-risk cytogenetic abnormalities (HRCAs) remains unclear.…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available